Ambry Genetics Epilepsy Genetic Testing Panels

Ambry Genetics has launched a new suite of seven genetic testing panels for epilepsy. The new epilepsy tests include: EpiFirst-Neonate, a targeted panel of genes most likely to cause neonatal seizures; EpiFirst-Fever, a targeted panel of genes most likely to cause febrile seizures; EpiFirst-IS, a targeted panel of genes most likely to cause infantile spasms; EpiFirst-Focal, a targeted panel of genes most likely to cause non-lesional focal epilepsy; PMEFirst, a targeted panel of genes more likely to cause progressive myoclonus epilepsy; PMENext, a broad panel of genes known to cause progressive myoclonus epilepsy; and EpiNext, a broad panel of genes known to cause a variety of epilepsy syndromes.

Testing can begin with a targeted gene panel, and move to a broader panel if desired. Alternatively, the broadest panel could be ordered as the first test if appropriate for the clinical situation. The flexible model gives healthcare providers the ability to control and choose their testing approach to best suit their patient. Test can be ordered stating on Nov. 9.